Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGentil, Fernanda
dc.contributor.authorBargieri, Daniel Y. [UNIFESP]
dc.contributor.authorLeite, Juliana A.
dc.contributor.authorFrancoso, Katia S.
dc.contributor.authorPatricio, Mariana B. M.
dc.contributor.authorEspindola, Noeli M.
dc.contributor.authorVaz, Adelaide J.
dc.contributor.authorPalatnik-de-Sousa, Clarisa B.
dc.contributor.authorRodrigues, Mauricio M. [UNIFESP]
dc.contributor.authorCosta, Fabio Trindade Maranhão [UNIFESP]
dc.contributor.authorSoares, Irene S.
dc.identifier.citationVaccine. Oxford: Elsevier B.V., v. 28, n. 38, p. 6183-6190, 2010.
dc.description.abstractThe Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development of a malaria vaccine against asexual stages of Plasmodium. We recently identified domain II (DII) of Plasmodium vivax AMA-1 (PvAMA-1) as a highly immunogenic region recognised by IgG antibodies present in many individuals during patent infection with P. vivax. the present study was designed to evaluate the immunogenic properties of a bacterial recombinant protein containing PvAMA-1 DII. To accomplish this, the recombinant protein was administered to mice in the presence of each of the following six adjuvants: Complete/Incomplete Freund's Adjuvant (CFA/IFA), aluminium hydroxide (Alum), Quil A, QS21 saponin, CpG-ODN 1826 and TiterMax. We found that recombinant DII was highly immunogenic in BALB/c mice when administered in the presence of any of the tested adjuvants. Importantly, we show that DII-specific antibodies recognised the native AMA-1 protein expressed on the surface of P. vivax merozoites isolated from the blood of infected patients. These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria. (C) 2010 Elsevier B.V. All rights reserved.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
dc.description.sponsorshipThe National Institute for Vaccine Development and Technology
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.publisherElsevier B.V.
dc.rightsAcesso restrito
dc.subjectPlasmodium vivaxen
dc.subjectRecombinant vaccineen
dc.titleA recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in miceen
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.description.affiliationUniv São Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 São Paulo, Brazil
dc.description.affiliationUniv Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, BR-13083862 Campinas, SP, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio de Janeiro, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 São Paulo, Brazil
dc.description.sponsorshipIDFAPESP: 2006/02832-0
dc.description.sourceWeb of Science
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.